

ICMJE DISCLOSURE FORM

Date: 16/05/2022
 Your Name: Amitesh Roy
 Manuscript Title: Gist: molecular heterogeneity and current challenges
 Manuscript number (if known): _____

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the **current manuscript only**.

The author's relationships/activities/interests should be **defined broadly**. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

In item #1 below, report all support for the work reported in this manuscript without time limit. For all other items, the time frame for disclosure is the past 36 months.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
Time frame: Since the initial planning of the work			
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	None	
Time frame: past 36 months			
2	Grants or contracts from any entity (if not indicated in item #1 above).	Merck, Specialized Therapeutics	
3	Royalties or licenses	None	
4	Consulting fees	None	

5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	Ipsen, BMS, MSD, Bei gene	
6	Payment for expert testimony	None	
7	Support for attending meetings and/or travel	None	
8	Patents planned, issued or pending	None	
9	Participation on a Data Safety Monitoring Board or Advisory Board	None	
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	None	
11	Stock or stock options	None	
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	None	
13	Other financial or non-financial interests	None	

Please summarize the above conflict of interest in the following box:

Dr. Roy received research grants from Merck and Specialized Therapeutics, and received honorarium from Ipsen, BMS, MSD and Bei Gene.

Please place an "X" next to the following statement to indicate your agreement:

X I certify that I have answered every question and have not altered the wording of any of the questions on this form.

ICMJE DISCLOSURE FORM

Date: 16/05/2022

Your Name: John Zalcborg

Manuscript Title: Gist: molecular heterogeneity and current challenges

Manuscript number (if known): _____

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the **current manuscript only**.

The author's relationships/activities/interests should be **defined broadly**. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

In item #1 below, report all support for the work reported in this manuscript without time limit. For all other items, the time frame for disclosure is the past 36 months.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
Time frame: Since the initial planning of the work			
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	None	
Time frame: past 36 months			
2	Grants or contracts from any entity (if not indicated in item #1 above).	None	
3	Royalties or licenses	None	
4	Consulting fees	Merck Serono, Targovax, Merck Sharp & Dohme, Halozyme, Lipotek,	

		Specialised Therapeutics, Center for Emerging & Neglected Diseases(CE), Deciphera, REVOLUTION MEDICINE, FivePHusion, Genor BioPharma, 1Globe Health Institute, Novotech	
5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	Specialised Therapeutics, Merck Serono, Targovax, Halozyme, Gilead Sciences, Deciphera	
6	Payment for expert testimony	None	
7	Support for attending meetings and/or travel	Merck Serono, AstraZeneca, Merck Sharp &Dohme, Deciphera, Sanofi	
8	Patents planned, issued or pending	None	
9	Participation on a Data Safety Monitoring Board or Advisory Board	None	
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	ICON Group	
11	Stock or stock options	Biomarin, Opthea, Amarin Corporation, Concert Pharmaceuticals, Frequency Therapeutics, Gilead Sciences, Madrigal Pharmaceuticals, UniQure, Zogenix, Orphazyme, Moderna Therapeutics, Twist Bioscience, Novavax	
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	None	
13		None	

	Other financial or non-financial interests		

Please summarize the above conflict of interest in the following box:

JZ received Consulting fees from Merck Serono, Targovax, Merck Sharp &Dohme, Halozyme, Lipotek, Specialised Therapeutics, Center for Emerging & Neglected Diseases(CE), Deciphera, REVOLUTION MEDICINE, FivePHusion, Genor BioPharma, 1Globe Health Institute and Novotech. JZ received payment or honoraria from Specialised Therapeutics, Merck Serono, Targovax, Halozyme, Gilead Sciences and Deciphera. JZ obtained support for attending meetings from Merck Serono, AstraZeneca, Merck Sharp &Dohme, Deciphera and Sanofi. JZ has Leadership role in ICON Group and he hold Stock or stock options in Biomarin, Opthea, Amarin Corporation, Concert Pharmaceuticals, Frequency Therapeutics, Gilead Sciences, Madrigal Pharmaceuticals, UniQure, Zogenix, Orphazyme, Moderna Therapeutics, Twist Bioscience and Novavax.

Please place an “X” next to the following statement to indicate your agreement:

X I certify that I have answered every question and have not altered the wording of any of the questions on this form.